GenScript Biotech
金斯瑞生物科技
Executive Summary
GenScript Biotech is a major Chinese life sciences tools and CDMO company with ~$500M revenue, best known as parent of US-listed Legend Biotech (CAR-T leader). Strong deal-making track record with global pharma partnerships for gene synthesis, biologics manufacturing, and research services. Clear BIOSECURE status reduces regulatory risk for US partnerships. Primarily a service provider rather than drug developer, making it an enabling partner for US pharma operations.
Structure: Listed on Hong Kong Stock Exchange (1548.HK) with operations primarily in China. Parent company of US-listed Legend Biotech (LEGN), indicating sophisticated cross-border corporate structure and experience with US regulatory compliance. Structure appears designed to facilitate international partnerships while maintaining Chinese operational base.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Fangliang Zhang 章方良 | Founder & Chairman | PhD, Duke University |
Ownership & Shareholder Structure
GenScript Biotech → Legend Biotech
GenScript Biotech is the majority shareholder of Legend Biotech, holding ~58% stake. Legend Biotech developed Carvykti (cilta-cel) in partnership with J&J.
GenScript Biotech → WuXi AppTec
GenScript gene synthesis competes with WuXi AppTec Genomics division.
BIOSECURE Risk
Clear BIOSECURE status with no BCC designation significantly reduces regulatory risk for US partnerships
Key Exposures:
- •Chinese data handling for US client projects
- •Supply chain dependencies for US operations
- •Potential future policy changes affecting CDMO services
Mitigation: Strong track record with US partnerships through Legend Biotech subsidiary demonstrates compliance capabilities
BD Intelligence
Therapeutic Areas:
Recent Deals: No specific deal data available, but established service relationships with global pharma through CDMO and research services
Approach: Approach as strategic service partner for gene synthesis, biologics manufacturing, or research capabilities rather than traditional drug asset licensing
Red Flags
- ⚠Limited pipeline visibility beyond service offerings
- ⚠Heavy dependence on Chinese operations for service delivery
- ⚠Potential IP exposure through extensive client service relationships
Quick Facts
- Key People
- 1
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 2
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.